Capital International Inc. CA Boosts Stock Position in Eli Lilly and Company $LLY

Capital International Inc. CA boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.6% in the third quarter, HoldingsChannel.com reports. The fund owned 200,026 shares of the company’s stock after purchasing an additional 17,582 shares during the period. Eli Lilly and Company accounts for 1.2% of Capital International Inc. CA’s holdings, making the stock its 17th largest position. Capital International Inc. CA’s holdings in Eli Lilly and Company were worth $152,620,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Capital International Investors increased its stake in Eli Lilly and Company by 6.1% during the third quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock worth $7,628,447,000 after purchasing an additional 579,381 shares during the period. Bank of Montreal Can boosted its stake in shares of Eli Lilly and Company by 8.9% in the third quarter. Bank of Montreal Can now owns 1,569,917 shares of the company’s stock valued at $1,197,846,000 after purchasing an additional 127,679 shares during the period. Legal & General Group Plc grew its holdings in shares of Eli Lilly and Company by 3.0% in the third quarter. Legal & General Group Plc now owns 5,383,999 shares of the company’s stock valued at $4,107,991,000 after purchasing an additional 154,714 shares in the last quarter. Banque Cantonale Vaudoise lifted its holdings in Eli Lilly and Company by 3.6% during the 3rd quarter. Banque Cantonale Vaudoise now owns 21,043 shares of the company’s stock worth $16,057,000 after buying an additional 727 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $2,060,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LLY shares. Guggenheim upped their price objective on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Scotiabank reissued an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Argus upped their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Berenberg Bank increased their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research report on Thursday, February 19th. Finally, UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,008.42 on Tuesday. The firm has a market capitalization of $951.30 billion, a PE ratio of 43.94, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock’s 50-day simple moving average is $1,044.23 and its 200-day simple moving average is $944.67.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the previous year, the company posted $5.32 earnings per share. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Launched an Employer Connect platform to engage employers and payers — a channel that could speed formulary conversations and uptake of Lilly’s weight‑management and diabetes medicines. Eli Lilly and Company (LLY) Announces the Launch of its Employer Connect Platform
• Positive Sentiment: Amazon Pharmacy expanded access to Lilly’s Zepbound KwikPen, widening retail distribution and patient convenience — likely to support Zepbound prescription volumes and recurring revenue. Amazon Pharmacy Expands Access to Eli Lilly’s Zepbound KwikPen for Weight Management
• Positive Sentiment: Announced a $500 million investment in South Korea’s biotech sector — strategic capital that could accelerate manufacturing, R&D collaborations and regional expansion of Lilly’s pipeline and commercial footprint. Eli Lilly (LLY) Is Making a Big Bet on South Korea’s Biotech Sector. Here’s Why
• Positive Sentiment: J.P. Morgan maintained a buy rating, reinforcing analyst support for Lilly’s growth thesis driven by GLP‑1 leadership and pipeline depth. J.P. Morgan Keeps Their Buy Rating on Eli Lilly & Co (LLY)
• Positive Sentiment: Coverage pieces continue to highlight Lilly’s dominant GLP‑1 franchises (Mounjaro, Zepbound) and pipeline assets — supporting the long‑term growth narrative even as valuation remains elevated.
• Neutral Sentiment: Market commentary noted Lilly outperformed the broader market in recent sessions, reflecting momentum trading around GLP‑1 exposure rather than new company‑specific data. Eli Lilly (LLY) Laps the Stock Market: Here’s Why
• Neutral Sentiment: Analyst/opinion pieces caution that LLY’s valuation is stretched — a reminder that upside may be tied to continued strong sales and pipeline progress rather than multiple expansion alone. Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?
• Negative Sentiment: A U.S. court certified a nationwide class of third‑party payors in racketeering litigation tied to Actos, raising potential legal and cash‑flow risk if liabilities materialize. This is a direct headline risk to watch. Actos Class Action Puts Eli Lilly Legal And Cash Flow Risks In Focus
• Negative Sentiment: Reportedly some basic Medicare plans may not adhere to the $50/month out‑of‑pocket cap for weight‑loss drugs under the agency model — a coverage/affordability uncertainty that could affect uptake and public perception. Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.